Affibody Medical Partnering

Affibody’s proprietary technology platform has a proven track record of developing candidate drugs targeting severe diseases. We choose to selectively collaborate with companies that have extensive knowledge in relevant therapeutic areas and a significant commitment in drug development and commercialization of biologics.

Izokibep partnerships

To achieve maximum development speed and rapid future market penetration, the global development of the company’s most advanced drug candidate, izokibep, is being conducted in collaboration with partners. In 2020 and 2021, respectively, Affibody partnered with Inmagene Biopharmaceuticals and ACELYRIN for the development of izokibep. Together, the company triad leads the development of izokibep in several autoimmune diseases where the protein IL-17A plays a foundational role.

To fully unlock the potential of the platform, Affibody seeks partnerships with leading companies that excel in their therapeutic areas

Our partners

Inmagene Biopharmaceuticals

In May 2020, Affibody and Inmagene Biopharmaceuticals announced a strategic partnership to develop and commercialize izokibep for multiple auto-immune diseases.

Inmagene Biopharmaceuticals will be responsible for commercialization in mainland China, Hong Kong, Taiwan, and Macau (Greater China), and South Korea, as well as development activities in the Asia Pacific region, excluding Japan.



In November 2021, Affibody and Acelyrin Inc announced a strategic partnership to develop and commercialize izokibep for multiple autoimmune diseases outside Inmagene’s territory.

Acelyrin will be responsible for development and commercialization globally, except within Inmagene’s development and commercialization territories, and for the development activities already initiated by Inmagene and Affibody outside Inmagene’s territory. Affibody has retained the marketing rights for the Nordic countries, with an option to extend such rights to the entire EU and the UK.



Affibody’s licensee Rallybio is a US-based biotechnology company founded by industrialists from the global biopharma company Alexion. The company develops therapies aimed at severe and rare diseases in hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. One of Rallybio’s lead programs, RLYB116, is based on an Affibody® molecule. RLYB116 is aimed at treating the rare disease paroxysmal nocturnal hemoglobinuria, and generalized myasthenia gravis.

Affibody is eligible for regulatory and sales-based milestone payments linked to progress in the regulatory process and commercialization of a finished product, as well as sales-based royalties.


GE Healthcare

Affibody has a partnership with GE Healthcare. The collaboration is focused on the development of PET-imaging agents.

Chiesi Group

In 2023, Affibody and Chiesi partnered for the development of innovative treatments for respiratory diseases. Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. Affibody and Chiesi Group will collaborate closely to develop novel Affibody® molecules as innovative treatments. The agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs.

Chiesi will fund all discovery, development, and subsequent commercialization worldwide, in line with its strategy and commitment to providing best-in-class level of care for people living with respiratory diseases, going beyond treatments and focusing on the patient experience. Affibody has retained the option to co-promote in the Nordic region.


Partnering Contacts

We believe that external collaborations are essential for our success.

Contact us